论文部分内容阅读
21世纪结核病的预防与治疗性疫苗的研制工作依然迫在眉睫。热休克蛋白HSP65是结核感染时的一种重要优势抗原,为此我们构建了结核杆菌HSP65DNA疫苗,并以IL-2和当归多糖(ASP)作为佐剂共同免疫小鼠,观察小鼠感染结核杆菌后的半数死亡时间与肺、肝、脾的病理变化,以及肺脏菌落计数,以评价此佐剂性DNA疫苗的预防作用。材料与方法 1.结核杆菌HSP65 NDA疫苗的构建及制备:根据结核杆菌HSP65基因序列,自行设计一对引物,以结核杆菌人型H37Rv标准毒力株基因组DNA为模板,经PCR循环扩增得到目的基因片
The development of 21st century prevention and treatment of tuberculosis vaccine is still imminent. Heat shock protein HSP65 is an important antigens in tuberculosis infection. Therefore, we constructed the Mycobacterium tuberculosis HSP65 DNA vaccine and co-immunized mice with IL-2 and Angelica polysaccharide (ASP) as adjuvants to observe the mice infected with Mycobacterium tuberculosis After half the time of death and lung, liver and spleen pathological changes, and lung colonies count to evaluate the adjuvant DNA vaccine prophylaxis. MATERIALS AND METHODS 1. Construction and preparation of Mycobacterium tuberculosis HSP65 NDA vaccine: According to the sequence of Mycobacterium tuberculosis HSP65, a pair of primers was designed by ourselves. The genomic DNA of Mycobacterium tuberculosis human H37Rv standard virulence strain was used as a template and amplified by PCR Gene fragment